Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《The Chinese Journal of Clinical Pharmacology》 2017-16
Add to Favorite Get Latest Update

Clinical trial of Xihuang capsules combined with compound matrine injection in the adjuvant treatment of colon cancer

YAN Li-kai;Department of General Surgery,Wufu District of Kaifeng Central Hospital;  
Objective To observe the clinical efficacy and safety of Xihuang capsules combined with compound matrine injection in the adjuvant treatment of colon cancer. Methods Fifty-two patients after colon cancer surgery were randomly divided into control group and treatment group with 26 cases per group. Control group was given compound matrine injection 2 mL,qd,intravenous drip. Treatment group was given Xihuang capsules 2. 0 g,bid,oral,on the basis of the control group.Two groups were treated for 56 d. The clinical efficacy,the levels of CD_3~+,CD_4~+,CD_8~+ T lymphocytes,CD_4~+/CD_8~+ ratio and adverse drug reactions were compared between two groups. Results After treatment,the total effective rates in the treatment and control groups were 53. 85%( 14/26 cases) and 26. 92%( 7/26 cases) with significant difference( P 0. 05). After treatment,the main indexes in treatment and control groups were compared: CD_3~+ were( 66. 08 ± 8. 11) %,( 54. 36 ± 6. 94) %;CD_4~+were( 46. 16 ± 5. 32) %,( 25. 46 ± 3. 16) %; CD_8~+ were( 23. 26 ± 3. 14) %,( 30. 57 ± 4. 28) %; CD_4~+/CD_8~+ were( 1. 98 ± 0. 26),( 0. 83 ± 0. 11),the differences were statistically significant( all P 0. 05). The adverse drug reactions in two groups were based on leukopenia,nausea and vomiting,liver and kidney dysfunction and thrombocytopenia. The incidences of adverse drug reactions in treatment and control groups were 46. 15% and 76. 92% with significant difference( P 0. 05). Conclusion The combination of Xihuang capsules and compound matrine injection has a definitive clinical efficacy in the adjuvant treatment of colon cancer,which can significantly reduce the damage of the immune function of patients and chemotherapy-related adverse drug reactions.
【Fund】: 河南省医学科技攻关计划基金资助项目(201203047)
【CateGory Index】: R735.35
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved